Head to head
Petrelintide against Cagrilintide
Two once-weekly amylin analogues in development, both making the same argument about tolerability relative to GLP-1 drugs. Neither is approved and they have never been randomised against each other.
Column A
PetrelintidePetrelintide (long-acting amylin analogue)
A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.
Column B
CagrilintideCagrilintide (long-acting amylin receptor agonist)
An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Side by side, on the facts we can check
| Attribute | Petrelintide | Cagrilintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 planned to start in the second half of 2026) | Investigational, not FDA-approved |
| Half-life | Supports weekly dosing | ~7 days |
| Molecular weight | 4,192 Da | ~3,700 Da |
| Mechanism | Agonizes amylin receptors to promote satiety and slow gastric emptying, used as a single-agent weight-loss approach. | Agonizes amylin receptors in the hypothalamus and brainstem to promote satiety and delay gastric emptying, complementing GLP-1 signaling. |
| Human studies cited | 2 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Petrelintide and Cagrilintide?
Petrelintide: A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results. Cagrilintide: An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Which has stronger research evidence, Petrelintide or Cagrilintide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Petrelintide profile were human work, against 3 of 3 for Cagrilintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Petrelintide and Cagrilintide FDA-approved?
Petrelintide: Investigational (Phase 3 planned to start in the second half of 2026). Cagrilintide: Investigational, not FDA-approved.
Related posts
Blog articles that cover Petrelintide or Cagrilintide, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.